RT @TMcCarty2010: Reminder for tonight! T-minus 7 hours to discussion time. #IDJClub.
RT @Boghuma: Looking forward to seeing many #IDtwitter and #Sciencetwitter folks join us for a lively discussion on #covid19 vaccines tonig…
RT @akelvinlab: Hi everyone! Please join me tonight 9 pm EDT for the @IDJClub discussion of the CanSino adenovirus type-5 (Ad5) vectored CO…
RT @JenniferSpicer4: Everyone join tonight!
RT @Boghuma: Looking forward to seeing many #IDtwitter and #Sciencetwitter folks join us for a lively discussion on #covid19 vaccines tonig…
RT @TMcCarty2010: Reminder for tonight! T-minus 7 hours to discussion time. #IDJClub. https://t.co/JVzzVCRfgs
Everyone join tonight!
RT @Boghuma: Looking forward to seeing many #IDtwitter and #Sciencetwitter folks join us for a lively discussion on #covid19 vaccines tonig…
RT @Boghuma: Looking forward to seeing many #IDtwitter and #Sciencetwitter folks join us for a lively discussion on #covid19 vaccines tonig…
RT @Boghuma: Looking forward to seeing many #IDtwitter and #Sciencetwitter folks join us for a lively discussion on #covid19 vaccines tonig…
Reminder about #IDJClub tonight at 9PM EDT to discuss phase 1 study of COVID19 vaccine candidate led by @Boghuma and @BradCutrellMD https://t.co/xzlUZ4TPi1 Join the discussion and invite your friends! Check out the visual abstract below. https://t.co/t
RT @akelvinlab: Hi everyone! Please join me tonight 9 pm EDT for the @IDJClub discussion of the CanSino adenovirus type-5 (Ad5) vectored CO…
RT @TMcCarty2010: Reminder for tonight! T-minus 7 hours to discussion time. #IDJClub.
RT @TMcCarty2010: Reminder for tonight! T-minus 7 hours to discussion time. #IDJClub. https://t.co/JVzzVCRfgs
Reminder for tonight! T-minus 7 hours to discussion time. #IDJClub.
RT @akelvinlab: Hi everyone! Please join me tonight 9 pm EDT for the @IDJClub discussion of the CanSino adenovirus type-5 (Ad5) vectored CO…
@ScottGottliebMD AR's (SAR's?): elevated liver enzymes, severe fever, fatigue, shortness of breath, hyperglycemia, myalgia, joint pain all at high rates by vax dev standards. Reported as "not clinically significant"? Need the details/outcomes? @vp @CDCDire
RT @akelvinlab: Hi everyone! Please join me tonight 9 pm EDT for the @IDJClub discussion of the CanSino adenovirus type-5 (Ad5) vectored CO…
RT @akelvinlab: Hi everyone! Please join me tonight 9 pm EDT for the @IDJClub discussion of the CanSino adenovirus type-5 (Ad5) vectored CO…
Hi everyone! Please join me tonight 9 pm EDT for the @IDJClub discussion of the CanSino adenovirus type-5 (Ad5) vectored COVID-19 vaccine study in the @TheLancet hosted by @GermHunterMD - @magiefrancis Melissa Rioux, Mary Foley, Mara McNeil I'm looking in
Primeira vacina a atingir o ensaio clínico de fase 1 foi considerada segura, bem tolerada e capaz de gerar uma resposta imune contra SARS-CoV-2 em humanos, aponta nova pesquisa publicada no The Lancet. Uma dose única da nova vacina COVID-19 (Ad5-nCoV) htt
RT @BcnVih: #PapersOnFire📄🌍 con la Dra. @NuriaCliment1 @TheLancet publica el 1r ensayo en humanos de una #vacuna para #COVID19 siendo cap…
RT @BcnVih: #PapersOnFire📄🌍 con la Dra. @NuriaCliment1 @TheLancet publica el 1r ensayo en humanos de una #vacuna para #COVID19 siendo cap…
#PapersOnFire📄🌍 con la Dra. @NuriaCliment1 @TheLancet publica el 1r ensayo en humanos de una #vacuna para #COVID19 siendo capaz de inducir anticuerpos neutralizantes y respuesta inmune de #célulasT específicas contra el virus📄https://t.co/4Dz2IuU6Rm 👉htt
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/JoQF995wtC
China reports first results of safety and immunogenicity of a recombinant adenvirus type-5 vectored COVID vaccine. https://t.co/ZKNOLO2b37
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
RT @LuisZuritaG: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/83WlSEehqU
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID19 #vaccine : a dose-escalation, open-label, non-randomised, first-in-human trial - @TheLancet https://t.co/ovamFK70uA
Thoughts? #MedTwitter https://t.co/sFDVFqgeUU
RT @SEMERGENap: 📙Seguridad, tolerabilidad e inmunogenicidad de una #vacuna #COVID19 vectorizada por adenovirus tipo 5 recombinante: el 1º e…
A little snippet of good news: The first human trial of a COVID-19 vaccine finds that it is safe, well-tolerated, and induces a rapid immune response: “These results represent an important milestone.” https://t.co/gMNegsoZYZ
Phase 1 COVID-19 vaccine trial using adenovirus vector was successful. 4-fold rising of neutralizing Ab was detected after 28 days in >75% of participants who received "high-dose" vaccine. Peak T cell response was in 2 weeks. https://t.co/VqsRJUdhTT htt
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/iWDWYRXE8r
RT @vishalpanchal85: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response - Research paper: https://t.…
Seguridad, tolerabilidad e inmunogenicidad de una vacuna frente a COVID-19 vectorizada con adenovirus recombinante tipo 5: estudio de escalada de dosis, abierto... https://t.co/t74fGBYdLV #COVID #MedTwitter @TheLancet https://t.co/iA8WngFtKI
No one is immune to the awesomeness of this novel journal club! Be there or be square 🤓 Hopefully my @umnmedresidency co-intern, @bhychang, can join us! #IDJClub #COVID19 #IDtwitter
Reminder that our next #IDJClub will be Monday June 8 (9pm EDT) when we will be discussing this phase 1 study of a COVID19 vaccine candidate. We hope you will join our discussion! https://t.co/xzlUZ5bq9z https://t.co/gp6Ygmemc6
RT @allergyuptodate: New - First human trial of #COVID19 vaccine finds it is safe and induces rapid production of neutralising antibodies &…
📙Seguridad, tolerabilidad e inmunogenicidad de una #vacuna #COVID19 vectorizada por adenovirus tipo 5 recombinante: el 1º ensayo en humanos de aumento de dosis, de etiqueta abierta, no aleatorizado. https://t.co/UAHyZArWbC Original: https://t.co/tnYUPSzM0r
Results from the first human trial of a #COVID19 vaccine suggest that it can safely confer immunity to the #SARSCoV2 virus 🦠 Find out more about this breakthrough study in @TheLancet: https://t.co/snnwhccakG https://t.co/IhYmbHUzN1
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/UIh9tjDiej
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @charlesweijer: Article in @TheLancet https://t.co/1itnvP9o6L
Article in @TheLancet https://t.co/1itnvP9o6L
RT @hserag: Will Trump buy the vaccine from China for Americans? Safety, tolerability, and immunogenicity of a recombinant adenovirus type…
Erste Studie zum chinesischen Impfstoff. (Kurzzusammenfassung: Die meisten Probanden entwickelten Antikörper, aber nur zum Teil in ausreichendem Maße.) https://t.co/HkfdNrc6sd
🛑Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial🛑 https://t.co/Sg2tPVerFA
Artículo sobre datos preliminares obtenidos en fase 1 de #vacuna para #Covid_19. Dan datos de: - seguridad - tolerabilidad - inmunogenicidad En adultos sanos, en China, tras 28 días de haber aplicado la vacuna. Lectura muy recomendable. https://t.co/67Ky
Will Trump buy the vaccine from China for Americans? Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/8l7MSHGmhg
RT @IDJClub: Thanks everyone for joining us tonight! We are back NEXT WEEK on Mon June 8, when we will be discussing a phase 1 trial of a…
初めて一流紙に登場した #COVID19 ワクチンは中国CanSino Biologics製。Ad5べクターでスパイクタンパクを発現させるもの。195人へのP1はtolerable and immunogenic。トップ集団を形成中:江蘇CDC。 https://t.co/dT2RuKuSoG
Some Positive News #COVID19 https://t.co/MFzf3LXnM1
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/uQvFYJeath
I’m wondering whether targeting the spike protein has the risk of cross-reactivity and a consequent autoimmune response 🤔https://t.co/qmJBsebYVN
RT @herzi38: Looks like a fun group to follow. #epitwitter are there other epi & infectious disease & global health journal clubs I should…